Kava pyrones and resin: studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain
- PMID: 1332016
- DOI: 10.1111/j.1600-0773.1992.tb00530.x
Kava pyrones and resin: studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain
Abstract
Kava, an intoxicating beverage prepared from the pepper plant Piper methysticum, is widely consumed by the indigenous peoples in the islands of the South Pacific. As the first of a series of studies on the neuropharmacological interactions of kava with CNS receptors we tested purified pyrones and kava resin for activity on GABA and benzodiazepine binding sites in rat and mouse brain membranes. Only weak activity was observed on GABAA binding sites in washed synaptosomal membranes prepared from rat brain and this was abolished by extraction of the membranes with Triton X-100, suggesting that lipid soluble components were involved. No effects were observed on GABAB binding sites in rat brain membranes in vitro. Kava resin and pyrones exerted some weak effects on benzodiazepine binding in vitro but this did not correlate with pharmacological activity. In addition, in ex vivo studies, no effects were observed on [3H]diazepam binding to brain membranes prepared from mice in which selected kava constituents were injected intraperitoneally, whereas similarly administered diazepam (5 mg/kg) inhibited [3H]diazepam binding by greater than 95%. Similar lack of activity was observed in in vivo binding studies; injection of kava resin failed to influence the CNS binding of the benzodiazepine-receptor ligand [3H]Ro15-1788 injected into mice prior to sacrifice. The pharmacological activities of kava resin and pyrones do not appear to be explained by any significant interaction with GABA or benzodiazepine binding sites.
Similar articles
-
Interaction of various Piper methysticum cultivars with CNS receptors in vitro.Planta Med. 2001 Jun;67(4):306-11. doi: 10.1055/s-2001-14334. Planta Med. 2001. PMID: 11458444
-
The antinociceptive actions of kava components in mice.Clin Exp Pharmacol Physiol. 1990 Jul;17(7):495-507. doi: 10.1111/j.1440-1681.1990.tb01349.x. Clin Exp Pharmacol Physiol. 1990. PMID: 2401103
-
Flunitrazepam photoaffinity labeling of the GABA(A) receptor reduces inhibition of [3H]Ro15-4513 binding by GABA.Eur J Pharmacol. 1990 Jun 12;188(6):391-7. doi: 10.1016/0922-4106(90)90199-8. Eur J Pharmacol. 1990. PMID: 2164940
-
Uridine receptor: discovery and its involvement in sleep mechanism.Sleep. 2001 May 1;24(3):251-60. doi: 10.1093/sleep/24.3.251. Sleep. 2001. PMID: 11322706 Review.
-
Toxicity of kava pyrones, drug safety and precautions--a case study.Phytomedicine. 2003;10 Suppl 4:68-73. doi: 10.1078/1433-187x-00300. Phytomedicine. 2003. PMID: 12807347 Review.
Cited by
-
A Review of Herbal Therapy in Multiple Sclerosis.Adv Pharm Bull. 2018 Nov;8(4):575-590. doi: 10.15171/apb.2018.066. Epub 2018 Nov 29. Adv Pharm Bull. 2018. PMID: 30607330 Free PMC article. Review.
-
Therapeutic potential of kava in the treatment of anxiety disorders.CNS Drugs. 2002;16(11):731-43. doi: 10.2165/00023210-200216110-00002. CNS Drugs. 2002. PMID: 12383029 Review.
-
Clinical pharmacokinetics of kavalactones after oral dosing of standardized kava extract in healthy volunteers.J Ethnopharmacol. 2022 Oct 28;297:115514. doi: 10.1016/j.jep.2022.115514. Epub 2022 Jun 28. J Ethnopharmacol. 2022. PMID: 35777607 Free PMC article.
-
Amides from Piper capense with CNS activity - a preliminary SAR analysis.Molecules. 2009 Sep 25;14(9):3833-43. doi: 10.3390/molecules14093833. Molecules. 2009. PMID: 19783959 Free PMC article.
-
Innovating through tradition: kava-talanoa as a culturally aligned medico-behavioral therapeutic approach to amelioration of PTSD symptoms.Front Psychol. 2025 May 27;16:1460731. doi: 10.3389/fpsyg.2025.1460731. eCollection 2025. Front Psychol. 2025. PMID: 40497110 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials